N-(3-fluoro-4-(2-arylthieno[3,2-b]pyridin-7-yloxy)phenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: A novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors

https://doi.org/10.1016/j.bmcl.2009.01.068Get rights and content

Abstract

A series of N-(3-fluoro-4-(2-arylthieno[3,2-b]pyridin-7-yloxy)phenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides targeting c-Met and VEGFR2 tyrosine kinases was designed and synthesized. The compounds were potent against these two enzymes with IC50 values in the low nanomolar range in vitro, possessed favorable pharmacokinetic profiles and showed high efficacy in vivo in several human tumor xenograft models in mice.

Graphical abstract

A series of N-(3-fluoro-4-(2-arylthieno[3,2-b]pyridin-7-yloxy)phenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides (II) targeting c-Met and VEGFR2 tyrosine kinases, based on our previous acetylthiourea series (I), was designed and synthesized. The new compounds were potent against these two enzymes with IC50 values in the low nanomolar range in vitro, possessed favorable pharmacokinetic profiles and showed high efficacy in vivo in several human tumor xenograft models in mice.

  1. Download : Download full-size image

References and notes (17)

  • B. Bilanges et al.

    Nat. Chem. Biol.

    (2008)
  • J. Cui

    Expert Opin. Ther. Patents

    (2006)
    J.J. Cui

    Expert Opin. Ther. Patents

    (2007)
    O. Abidoye et al.

    Rev. Recent Clin. Trials

    (2007)
    H.Y. Zou et al.

    Cancer Res.

    (2007)
    P.-P. Kung et al.

    Eur. J. Med. Chem.

    (2008)
    S.F. Bellon et al.

    J. Biol. Chem.

    (2008)
    G.M. Schroeder et al.

    Bioorg. Med. Chem. Lett.

    (2008)
    Z.-W. Cai et al.

    Bioorg. Med. Chem. Lett.

    (2008)
    B.K. Albrecht et al.

    J. Med. Chem.

    (2008)
    P.M. Comoglio et al.

    Nat. Rev. Drug Disc.

    (2008)
    L. Liu et al.

    J. Med. Chem.

    (2008)
    K.S. Kim et al.

    J. Med. Chem.

    (2008)
    N.D. D’Angelo et al.

    J. Med. Chem.

    (2008)
  • J.G. Christensen et al.

    Cancer Res.

    (2003)
    P.C. Ma et al.

    Clin. Cancer Res.

    (2005)
    G.A. Smolen et al.

    Proc. Natl. Acad. Sci. U.S.A.

    (2006)
  • A.G. Bayer

    Chem. Abstr.

    (1975)
    J.A. Maclaren

    Aust. J. Chem.

    (1977)
    W. Su et al.

    J. Chem. Res. Synop.

    (2000)
  • P. Blume-Jensen et al.

    Nature

    (2001)
  • P.C. Ma et al.

    Cancer Metast. Rev.

    (2003)
    C. Birchmeier et al.

    Nat. Rev. Mol. Cell Biol.

    (2003)
    J.G. Christensen et al.

    Cancer Lett.

    (2005)
    S. Corso et al.

    Trends Mol. Med.

    (2005)
    C. Boccaccio et al.

    Nat. Rev. Cancer

    (2006)
    B. Peruzzi et al.

    Clin. Cancer Res.

    (2006)
    B.S. Knudsen et al.

    Cur. Opin. Gen. Dev.

    (2008)
    L. Toschi et al.

    Clin. Cancer Res.

    (2008)
  • N. Ferrara et al.

    Nat. Med.

    (2003)
    K. Paz et al.

    Front. Biosci.

    (2005)
  • T.L. Underiner et al.

    Curr. Med. Chem.

    (2004)
    J. Dumas et al.

    Expert. Opin. Ther. Patents

    (2005)
    Y. Loriot et al.

    Oncologie

    (2006)
    A. Morabito et al.

    The Oncologist

    (2007)
    A.S. Kiselyov et al.

    Expert Opin. Investig. Drugs

    (2007)
    E. Cabebe et al.

    Expert Opin. Investig. Drugs

    (2007)
    H. Zhong et al.

    Curr. Top. Med. Chem.

    (2007)
    S. Schenone et al.

    Cur. Med. Chem.

    (2007)
There are more references available in the full text version of this article.

Cited by (0)

Present address: Isis Pharmaceuticals, 1896 Rutherford Road, Carlsbad, CA 92008, USA.

View full text